Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© 2018, Akadémiai Kiadó, Budapest, Hungary. Niobium-90 (90Nb) is a positron emitting radionuclide that exhibits attractive characteristics for use in the design and synthesis of radioimmunoconjugates. In the current study we have investigated 90Nb as a possible future isotope for immuno-PET. Prior to 90Nb in vivo studies, this paper describes in vitro and ex vivo studies using a Niobium-95 (95Nb)-monoclonal antibody analogue. 95Nb has a half-life of 35 days and is convenient for long-term studies. 95Nb-labelled bevacizumab was evaluated for early antiangiogenic tumor response assessment and the results were compared with other well established PET nuclides for immuno-PET. 95Nb was quantitatively recovered (> 95%) from irradiated natural Zr in a multistep separation. Bevacizumab was modified with the Df-Bz-NCS (Df) chelate and labelled with previously separated 95Nb. Stability of 95Nb-Df-bevacizumab was evaluated in saline and in human plasma over 7 days presenting > 96% and > 94% of intact product, respectively. Biodistribution ex vivo studies were performed on M165 tumor-bearing mice. 95Nb was obtained in high purity (99.999%) and high radioactivity concentration (1.7 MBq/µL) in a total volume of 200 µL oxalic acid (0.1 M), ready for labelling. Df-bevacizumab labelling was efficient (> 95%) and in vitro stability of 95Nb-Df-bevacizumab was high. Ex vivo studies displayed good tumor-to-background ratios, optimum after 2 days p.i., after iv injection of 20 µg of antibody per mouse. 95Nb was successfully produced and purified from the irradiated target. Labeling of bevacizumab pre-modified with desferrioxamine was achieved in high yields. After in vitro stability of 95Nb-Df-bevacizumab was demonstrated, ex vivo biodistribution studies showed specific tumor uptake in M165 tumor-bearing mice. Consequently, in vivo studies with 90Nb-Df-bevacizumab and small animal PET are in preparation, and we expect that 90Nb-Df-conjugated antibodies will show potential for immuno-PET.

Original publication

DOI

10.1007/s10967-018-6314-2

Type

Journal article

Journal

Journal of Radioanalytical and Nuclear Chemistry

Publication Date

01/12/2018

Volume

318

Pages

1991 - 1997